MarketPulse

base editing

4 articles
The Motley FoolThe Motley Fool··Robert Izquierdo

Beam Therapeutics CEO Sells $739K in Stock, But Strong Financials Suggest Confidence Remains

Beam Therapeutics CEO John Evans sold 30,078 shares for $739K via pre-planned tax obligation. Strong 2025 revenue growth and $1.2B cash reserves indicate company health.
BEAMbiotechinsider sale
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Beam Therapeutics' BEAM-302 Shows Promise in Alpha-1 Deficiency, Eyes Pivotal Trial

Beam Therapeutics reports positive Phase 1/2 data for BEAM-302 base editing therapy in alpha-1 antitrypsin deficiency, advancing toward pivotal development in late 2026.
BEAMclinical trialgene therapy
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Beam Therapeutics Secures $500M Credit Facility to Fund Sickle Cell Therapy Launch

Beam Therapeutics secures $500M credit facility from Sixth Street Partners to fund commercial launch of its sickle cell therapy, with payments tied to clinical and regulatory milestones.
BEAMcommercializationsickle cell disease
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Beam Therapeutics to Unveil 2025 Results and Novel Liver Disease Program

Beam Therapeutics will discuss 2025 results and unveil a new liver disease program on February 24, 2026. The company also secured FDA alignment for accelerated approval of BEAM-302.
BEAMFDA approvalbase editing